Trial Profile
Phase 1 Trial of Denosumab for Prevention of Bone Complications After Allogenic Hematopoietic Stem Cell Transplantation in Children
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 12 Sep 2018
Price :
$35
*
At a glance
- Drugs Denosumab (Primary)
- Indications Bone disorders
- Focus Adverse reactions
- 04 Sep 2018 Status changed from not yet recruiting to withdrawn prior to enrolment due to lack of funding.
- 12 Oct 2016 Planned End Date changed from 1 Mar 2022 to 1 Oct 2022.
- 12 Oct 2016 Planned primary completion date changed from 1 Mar 2022 to 1 Oct 2022.